Advanced search
Publication Cover
Scandinavian Journal of Infectious Diseases Volume 32, 2000 - Issue 2
Submit an article Journal homepage
137
Views
83
CrossRef citations to date
0
Altmetric
Research Article

Hyperlipidemia Associated with HIV Protease Inhibitor Use: Pathophysiology, Prevalence, Risk Factors and Treatment

Scott R. Penzak, Susan K. Chuck Mercer University, Southern School of Pharmacy, 3001 Mercer University Drive, Atlanta, USA
Pages 111-123 | Published online: 08 Jul 2009

  • Kakuda TN, Struble KA, Piscitelli SC. Protease inhibitors for the treatment of human immunodeficiency virus infection. Am J Health-Syst Pharm 1998; 55: 233–54.
  • Palella FJ Jr., Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853–60.
  • Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337: 725–33.
  • Carr A. Protease inhibitor-induced lipodystrophy. In: Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, California; 1998 September 24–27. Abstract S–151.
  • Sellmeyer DE, Grunfeld C. Endocrine and metabolic disturbances in human immunodeficiency virus infection and the acquired immune deficiency syndrome. Endocr Rev 1996; 17: 518–32.
  • Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J, Pierson RN. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989; 86: 27–31.
  • Alvarez C, Ramox A. Lipids, lipoproteins, and apoproteins in serum during infection. Clin Chem 1986; 32: 142–5.
  • Kerttula Y, Weber TH. Serum lipids in viral and bacterial meningitis. Scand J Infect Dis 1986; 18: 211–5.
  • Sammalkorpi K, Valtonen V, Kerttula Y, Nikkila E, Taskinen MR. Changes in serum lipoprotein pattern induced by acute infections. Metabolism 1988; 37: 859–65.
  • Grunfeld C, Kotler DP, Shigenaga JK, Doerrler W, Tierney A, Wang J, et al. Circulating interferon-a levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1991; 91: 154–62.
  • Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrin Metab 1992; 74: 1045–52.
  • Hellerstein MK, Grunfeld C, Wu K, Christiansen M, Kaempfer S, Kletke C, et al. Increased De Novo Hepatic lipogenesis in human immunodeficiency virus infection. J Clin Endocrin Metab 1993; 76: 559–65.
  • Constans J, Pellegrin JL, Peuchant E, Dumon MF, Pellegrin I, Sergeant C, et al. Plasma lipids in HIV-infected patients: a prospective study in 95 patients. Eur J Clin Invest 1994; 24: 416–20.
  • Mildvan D, Machado SG, Wilets I, Grossberg SE. Endogenous interferon and triglyceride concentrations to assess response to zidovudine in AIDS and advanced AIDS-related complex. Lancet 1992; 339: 453–6.
  • Carr A, Samaras K, Chisolm DJ, Cooper DA. Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance. Lancet 1998; 352: 1881–3
  • Lenhard JM, Weiel JE, Paulik MA, Miller L, Ittoop O, Blanchard SG, and Furfine ES. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro. Presented at: 6th Conference of Retroviruses and Opportunistic Infections; January 31–February 4, 1999; Chicago, IL. Abstract 666.
  • Lenhard JM, Weiel JE, Paulik MA, Lehmann JM, Koszalka G, Furfine ES. Indinavir enhances retinoic acid signaling nelfinavir, saquinavir, and ritonavir inhibit retinoid effects in vitro. Presented at: 6th Conference of Retroviruses and Opportunistic Infections; January 31–February 4, 1999; Chicago, IL. Abstract 665.
  • Herz J. The LDL-receptor-related protein – portrait of a multifunctional receptor. Curr Opin Lipidol 1993; 4: 107–13.
  • Baril L, Idhammoou A, Beucler I, Coutellier A, Valantin MA, Caumes E, et al. Are the decreased lipolytic enzyme activities responsible for the hypertriglyceridemia in PT-treated patients? Presented at: 6th Conference of Retroviruses and Opportunistic Infections; January 31–February 4, 1999; Chicago, IL. Abstract 664.
  • Danner SA, Carr A, Leonard JM, Lehman LM, Gudiol F, Gonzales J, et al. For the European-Australian Collaborative Ritonavir Study Group. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, and inhibitor of HIV-1 protease. N Engl J Med 1995; 333: 1528–33.
  • Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51–8.
  • Viraben R, Aquilina C. Indinavir-associated lipodystrophy. AIDS 1998; 12: F37–9.
  • Sullivan AK, Nelson MR. Marked hyperlipidemia on ritonavir therapy. AIDS 1997; 11: 938–9.
  • Vancouwenberghe C, King JH, Gordon J, McNulty J, Smith B, Mojica M. Clinical investigation of the incidence and severity of elevated cholesterol (CH) and triglycerides (TG) in AIDS patients receiving protease inhibitor (PI) therapy. In: Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, California; 1998 September 24–27. Abstract I–69.
  • Gaultier C, Musikanth P, Ruane PJ, Zakowski PC, Sokolov RJ, Uman SJ. Incidence of avascular necrosis of the hip in HIV-infected individuals on HAART. In: Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, California; 1998 September 24–27. Abstract I–71.
  • Vail M, Goldman M, Frank M, Cushing H, Wheat J, Deeg M, et al. Screening for hyperglycemia and hyperlipidemia in HIV-infected persons receiving protease inhibitors. In: Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, California; 1998 September 24–27. Abstract I–72.
  • Nelson MR, Moyle G, Newell A, Feher M, Gazzard BG. The incidence of hyperlipidemia with protease inhibitors (PI). In: Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, California; 1998 September 24–27. Abstract I–87.
  • Hewitt RG, Shelton MJ, Esch LD. Gemfibrozil effectively lowers protease inhibitor-associated hypertriglyceridemia in HIV-1 + patients. In: Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, California; 1998 September 24–27. Abstract I–88.
  • Rothstein AM, Caldwell RD, Allmon C, Zolopa AR, Montoya JG. Investigation of protease inhibitor-associated hypercholesterolemia in a University-based HIV clinic. In: Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, California; 1998 September 24–27. Abstract I–91.
  • Green R, Raghavan S, Levin K, Stanton M, El-Sadr W. Change in weight, body composition, and serum lipids prior to and after initiation of protease inhibitors. In: Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, California; 1998 September 24–27. Abstract I–94.
  • Keruly JC, Mehta S, Chaisson RE, Moore RD. Incidence and factors associated with the development of hypercholesterolemia and hyperglycemia in HIV-infected patients using a protease inhibitor. In: Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, California; 1998 September 24–27. Abstract I–95.
  • Michelet C, Bellissant E, Delfraissy JF, Arvieux C, Ruffault A, Stagnetto C, et al. Safety and efficacy of a combination of ritonavir and saquinavir added to AZT + 3TC in HIV infected patients. In: Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada; 1997 September 28-October 1. Abstract I–202.
  • Bonnet E, Cuzin L, Sailler L, Obadia M, Marchou B, Caron PH, et al. Associated lipodystrophy metabolic disorders due to protease inhibitor containing regimens. Presented: 12th World AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland. Abstract 12299.
  • Pollner J, Aronson NE, McHugh S, Nielson R, Hawkes C. Significant increases in serum cholesterol are seen among HIV patients taking protease inhibitors. Presented: 12th World AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland. Abstract 12269.
  • Duncombe C, Bloch M, Austin D, Quan D. Reversal of hyperlipidemia in patients switching therapy to nelfinavir. Presented: 12th World AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland. Abstract 12287.
  • Henry K. Lipid abnormalities associated with use of protease inhibitors: prevalence, clinical sequelae and treatment. Presented: 12th World AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland. Abstract 12319.
  • Dong K, Flynn MM, Dickinson BP, Rich JD, Tashima K, Flanigan TP, et al. Changes in body habitus in HIV( + ) women after initiation of protease inhibitor therapy. Presented: 12th World AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland. Abstract 12373.
  • Bernasconi E, Carota A, Magenta L, Pons M, Russotti M, Moccetti T, et al. Metabolic changes in HIV-infected patients treated with protease inhibitors. Presented: 12th World AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland. Abstract 12375.
  • Chang E, Deleo M, Liu YT, Tetreault D, Beall G. The effects of antiretroviral protease inhibitors (Pis) on serum lipids and glucose in HIV-infected patients. Presented: 12th World AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland. Abstract 12381.
  • Papadopoulos AI, Evangelopoulou EP, Nicolaidi NA, Zolotas ZN, Groutsis GT, Montsenigos MT, et al. Serum lipid changes in HIV-infected patients under combination therapy containing a protease inhibitor. Presented: 12th World AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland. Abstract 60118.
  • Martinez E, Casamitjana R, del Rio A, Mallolas J, Miro JM, Gatell JM. Chronic use of protease inhibitors is associated with hormonal abnormalities in otherwise healthy adult HIV-1 infected individuals. Presented: 12th World AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland. Abstract 60648.
  • Mulligan K, Tai VW, Algren H, Chernoff DN, Lo JC, Schambelan M. Evidence of unique metabolic effects of protease inhibitors. Presented at: 5th Conference of Retroviruses and Opportunistic Infections; February 1–5, 1998; Chicago, IL. Abstract 414.
  • Watson DC, Farley JJ. Hypercholesterolemia in children treated with HIV protease inhibitors. Presented at: 6th Conference of Retroviruses and Opportunistic Infections; January 31–February 4, 1999; Chicago, IL. Abstract 435.
  • Tsiordras S, Mantzoros C, Hammer SM, Samore M. Effects of protease inhibitor use on hyperglycemia and hyperlipidemia: a five year analysis. Presented at: 6th Conference of Retroviruses and Opportunistic Infections; January 31 – February 4, 1999; Chicago, IL. Abstract 643.
  • Lee D, Mathews WC. Prevalence and risk factors for hyperglycemia, dyslipidemia, and coronary disease among HIV-infected patients on initial protease inhibitor therapy. Presented at: 6th Conference of Retroviruses and Opportunistic Infections; January 31–February 4, 1999; Chicago, IL. Abstract 644.
  • Walli RK, Michl GM, Segerer S, Herfort O, Dieterle T, Demant T, Bogner JR, Goebel FD. Dyslipidemia and insulin resistance in HIV-infected patients treated with reverse transcriptase inhibitors alone and in combination with protease inhibitors. Presented at: 6th Conference of Retroviruses and Opportunistic Infections; January 31–February 4, 1999; Chicago, IL. Abstract 645.
  • Robertson M, Nessly M, Aversa D, Leavitt R. Changes in serum cholesterol and triglyceride levels in patients treated with indinavir or NRTIs. Presented at: 6th Conference of Retroviruses and Opportunistic Infections; January 31 – February 4, 1999; Chicago, IL. Abstract 648.
  • Thompson M, Gable J, Lawrence J, Rimland D, McCarthy W and the AIDS Research Consortium of Atlanta ASD Investigators. The prevalence of hypertriglyceridemia in HIV infected individuals who have been exposed to various antiretroviral drug classes since January 1996. Presented at: 6th Conference of Retroviruses and Opportunistic Infections; January 31–February 4, 1999; Chicago, IL. Abstract 649.
  • Currier J, Clark R, Squires K, Till M, Grieger P, Zorilla C, Gersten M, Wilcox N, Schultz M, Zhang M. Women first: durable response with dual protease inhibitor therapy without significant elevations in lipids. Presented at: 6th Conference of Retroviruses and Opportunistic Infections; January 31–February 4, 1999; Chicago, IL. Abstract 663.
  • Carr A, Thorisdottir A, Samaras K, Kaufmann GR, Chisolm DJ, Cooper DA. Reversibility of protease inhibitor (PI) lipodystrophy syndrome on stopping PIs or switching to nelfinavir. Presented at: 6th Conference of Retroviruses and Opportunistic Infections; January 31–February 4, 1999; Chicago, IL. Abstract 668.
  • Talbert RL. Hyperlipidemia. In: Dipiro JT, Talbert RL, Yee CG, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach. Connecticut: Appleton and Lange, 1997: 459–89.
  • Sprecher DL. Triglycerides as a risk factor for coronary artery disease. Am J Cardiol 1998; 82: 49U–56U.
  • National Cholesterol Education Program: Second report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation 1994; 89: 1329–445.
  • Klein D, Sidney S, Hurley L, Iribarren C. Do protease inhibitors increase the risk for coronary heart disease among HIV positive patients? Presented at: 6th Conference of Retroviruses and Opportunistic Infections; January 31–February 4, 1999; Chicago, IL. Abstract 657.
  • Coplan P, Nikas A, Saah A, Nessly M, Doll L, Leavitt R, et al. No association observed between indinavir therapy for HIV-AIDS and myocardial infarction in 4 clinical trilas with 2,825 subjects. Presented at: 6th Conference of Retroviruses and Opportunistic Infections; January 31–February 4, 1999; Chicago, IL. Abstract 658.
  • Juette A, Salzberger B, Franzen C, Roemer K, Diehl V, Faetkenheuer G. Increased morbidity from severe coronary heart disease in HIV-patients receiving protease inhibitors. Presented at: 6th Conference of Retroviruses and Opportunistic Infections; January 31–February 4, 1999; Chicago, IL. Abstract 656.
  • Ruiz L, Bonjoch A, Paredes R, Johnston S, Arno A, Romeu J, et al., for the LD Study Group ‘irsiCaixa’ Foundation. A multi-center, randomized, open-label, comparative trial of the clinical benefit of switching the protease inhibitor (PI) by nevirapine (NVP) in HAART-experienced patients suffering from lipodystrophy (LD). Presented at: 6th Conference of Retroviruses and Opportunistic Infections; January 31–February 4, 1999; Chicago, IL. Abstract LB–14.
  • Moyle G, Baldwin C, Dent N, Gazzard B. Management of indinavir-associated metabolic changes by substitution with efavirenz in virologically controlled HIV + persons.. Presented at: 6th Conference of Retroviruses and Opportunistic Infections; January 31–February 4, 1999; Chicago, IL. Abstract 669.
  • Martinez E, Lozano L, Conget I, Casamitjana R, Gatell J. Reversion of lipodystrophy after switching HIV-1 protease inhibitors to nevirapine. Presented at: 6th Conference of Retroviruses and Opportunistic Infections; January 31 – February 4, 1999; Chicago, IL. Abstract 670.
  • CDC. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR 1998; 47(no. RR-5); Updated: May, 1999: at http://www.hivatis.org.
  • Henry K, Melroe H, Huebesch J, Hermundson J, Simpson J. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet 1998; 352: 1031–2.
  • Christians U, Jacobsen W, Floren LC. Metabolism and drug interactions of 3-hydroxy-3-methyl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar. Pharmacol Ther 1998; 80: 1–34.
  • Anonymous. The Medical Letter on Drugs and Therapeutics. 1998; 40: 117–22.
  • Bertz RJ, Granneman. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997; 32: 210–58.
  • Miller DB, Spence JD. Clinical Pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet 1998; 34: 155–62.
  • Packard CJ. Overview of fenofibrate. Eur Heart J 1998; 19 Suppl A: A62–5.
  • Lees RS, Lees AM. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. N Engl J Med 1995; 333: 664–5.
  • Norman DJ, Illingworth DR, Munson J, Hosenpud J. Myolysis and acute renal failure in a heart-transplant patient receiving lovastatin. N Engl J Med 1988; 318: 46–7.
  • McKenney JM, Proctor JD, Harris S, Chinchili VM. A comparison of the efficacy and toxic effects of sustained-vs immediate-release niacin in hypercholesterolemic patients. JAMA 1994; 271: 672–7.
  • Walli RK, Michl GM, Bogner JR, Goebel FD. Effects of the PPAR-(gamma) activator troglitazone on protease inhibitor associated peripheral insulin resistance. Presented at: 6th Conference of Retroviruses and Opportunistic Infections; January 31–February 4, 1999; Chicago, IL. Abstract 673.
  • Torres R, Unger K. The effect of recombinant human growth hormone on protease-inhibitor-associated fat maldistribution syndrome. Presented at: 6th Conference of Retroviruses and Opportunistic Infections; January 31–February 4, 1999; Chicago, IL. Abstract 675.
  • Saint-Marc T, Touraine JL. Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor (PI) therapy. Presented at: 6th Conference of Retroviruses and Opportunistic Infections; January 31–February 4, 1999; Chicago, IL. Abstract 672.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.